SomnoMed Limited (ASX: SOM) has once more declared record unit sales for the 4th quarter to June 2011. Non-stop growth in SomnoDent® sales quantities in the June quarter by 32% over the same period last year was reproduced in the 7,323 units sold.
This product has been driven by record sales in international communities. The USA and European regions both increased 27% and 69% correspondingly over the same quarter last year. The APAC region has reflected 17% increase over QTR 3, with record sales in the June month bringing whole profits for SomnoMed in the fourth quarter to $3.3 million. The new US office, now based in Dallas-Frisco, Texas, attained record sales in the June month, with the European territory showing the same results.
CEO Mr. Ralf Barschow, SomnoMed’s commented, “The trends achieved in this quarter reiterate our capability to increase unit sales and incomes of the business, especially within the US and Europe, which are above standard within the Sleep Disordered Breathing industry. The record sales accomplished in June for all parts were very heartening; particularly on the back of a very victorious SLEEP 2011 congress in Minneapolis attended by SomnoMed.”
From a international point of view SomnoMed organizes direct operations in three global territories. Following the sustainable growth in Europe, SomnoMed is mounting its business activities, with new offices to be launched in France and Germany, as well as addition new employees to our European headquarters in Zurich, Switzerland. SomnoMed Nordic is moving into new services in Stockholm, with a broader range of clinical training and scientific services. In Israel a special distribution contract with SleepDent Limited has been signed, covering all crucial sleep centers and hospitals in that country.
“I am very conceited for SomnoMed to have shaped the exclusive partnership with SleepDent Limited in Israel. After a widespread clinical trial for over a year linking patients not accepting a CPAP treatment, the consequences once again have shown the clinical success of a SomnoDent® therapy in mild, moderate and severe cases,” said Mr. Barschow.
Mr. Barschow further said, “We keep on setting up our worldwide presence in all territories applicable for a SomnoDent® therapy. With above 70,000 clinically recognized treatments, SomnoDent® is clearly documented and unrivalled as the world’s no.1 oral appliance for obstructive sleep apnea.”
SomnoMed Limited had $3.95 million in cash available at 30 June 2011.
